Phaseline

Companies › Onchilles Pharma

Onchilles Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jul 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
N17350
Recombinant mutant porcine pancreatic elastase (PPE) targeting the neutrophil elastase (EL
ELANEPhase 1Neoplasms, Solid TumorJul 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07339176N17350Phase 1Neoplasms, Solid TumorOncologyJul 2028

Targets

ELANE (1)

Companies with the same targets

CSL Behring Grifols Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.